ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: Patient and graft survival, CD3 subset, infection, and cost analysis

Transplantation Proceedings

Volumn 30, Issue 4, 1998, Pages 1351-1352

  Kumar, M S A ^a,b   Cahill, K ^a   Kumar, A M S ^a   Panigrahi, D ^a   Seirka, D ^a   Singleton, R ^a   Al Abdullah, I H ^a   Laskow, D A ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b ALLEGHENY UNIVERSITY HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; CADAVER KIDNEY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; T LYMPHOCYTE SUBPOPULATION;

EID: 0031831899     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)00272-3     Document Type: Conference Paper

References (3)

1. Abouna GM, Al-Abdullah IH, Kelly-Sullivan D, et al: Transplantation 11:1564, 1995
2. Kumar MSA, Stephan R, Chui J, Transplant Proc 25:3097, 1993
3. Simpson MA, Monaco AP: In: Chatenoud L (ed): Monoclonal Antibodies in Transplantation. Austin, Tex: R.G. Landes Company; 1995, p1.